drugset / Trial / NCT01045577

A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT01045577

Phase 2 Completed 25 enrolled AB Science
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the activity of oral AB1010 in adults patients with moderate to severe chronic plaque psoriasis

Timeline

Start
2005-09
Primary completion
2006-01
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Masitinib Small molecule 3 mg/kg Oral
Comparator Masitinib Small molecule 6 mg/kg Oral

Indications